Repositioning Candidate Details
Candidate ID: | R0947 |
Source ID: | DB06224 |
Source Type: | investigational |
Compound Type: | small molecule |
Compound Name: | Alicaforsen |
Synonyms: | Alicaforsen |
Molecular Formula: | -- |
SMILES: | -- |
DrugBank Description: | -- |
CAS Number: | 185229-68-9 |
Molecular Weight: | |
DrugBank Indication: | Investigated for use/treatment in crohn's disease and ulcerative colitis. |
DrugBank Pharmacology: | -- |
DrugBank MoA: | Alicaforsen selectively inhibits ICAM‑1 gene expression. Over-expression of ICAM‑1 occurs in a wide variety of inflammatory disorders, including ulcerative colitis (UC), pouchitis and tissues in the eye, gastrointestinal teact, lungs and skin. UC is an inflammatory bowel disease of the colon, a part of the large intestine, and pouchitis is an inflammation of the surgically constructed internal pouch created in UC patients when their diseased colons are removed. Alicaforsen is a RNase H dependent phosphorothioate-modified antisense oligodeoxynucleotide inhibitor which shuts down specific sequences of intracellular adhesion molecule 1 (ICAM1) mRNA and thus production of ICAM1, which prevents the inflammatory response. ICAM is a cell surface glycoprotein (immunoglobulin superfamily) which facilitates leukocyte adhesion and antigen presentation in the intestinal mucosa. Alicaforsen hybridizes the oligonucleotide strand with the target mRNA to suppress expression of ICAM1. |
Targets: | -- |
Inclusion Criteria: | Therapeutic strategy associated |

Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
---|---|---|---|---|---|
S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
---|
Diseases ID | DO ID | Disease Name | Definition | Class |
---|